Result of AGM

Redx Pharma plc

14 March 2024

 

REDX PHARMA PLC

("Redx" or the "Company")

Result of Annual General Meeting

Alderley Park, UK, 14 March 2024 Redx (AIM:REDX), the clinical-stage biotechnology company focused on discovering and developing novel, small molecule, targeted therapeutics for the treatment of fibrotic disease and cancer today announces that its Annual General Meeting was held at 11am on 14 March 2024, with all resolutions passed by substantial majorities.

The table below sets out the details of the votes put to shareholders:

Resolution number	Resolution name	Number of votes for & discretionary	% of votes for & discretionary	Number of votes against	% of votes against	% of votes withheld*	Total votes cast (including withheld)
1	Receive the Company's annual accounts	351,887,218	94.48%	20,551,504	5.52%	0.00%	372,438,722
2	Re-appoint Ernst & Young as auditors	372,434,833	100.00%	2,586	0.00%	0.00%	372,438,722
3	Elect Dr Joseph Anderson as a director	372,408,267	99.99%	3,889	0.00%	0.01%	372,438,722
4	Re-elect Dr Jane Griffiths as a director	372,407,145	99.99%	5,011	0.00%	0.01%	372,438,722
5	Re-elect Peter Presland as a director	351,851,226	94.47%	20,558,505	5.52%	0.01%	372,438,722
6	Re-elect Dr Robert Scott as a director	351,854,954	94.47%	20,557,202	5.52%	0.01%	372,438,722
7	Authorise the directors to allot shares	372,396,854	99.99%	41,868	0.01%	0.00%	372,438,722
8	Disapply pre-emption rights	372,266,621	99.96%	164,843	0.04%	0.00%	372,438,722

*A vote withheld is not a vote in law and is not counted in the calculation of the proportion of votes 'For' or 'Against'

For further information, please contact:
Redx Pharma Plc UK Headquarters Caitlin Pearson, Head of Communications  [e-mail]					T: [phone]
SPARK Advisory Partners (Nominated Adviser)					T: [phone]
Matt Davis/ Adam Dawes
WG Partners LLP (Joint Broker)					T: [phone]
Claes Spång/ Satheesh Nadarajah/ David Wilson
Panmure Gordon (UK) Limited (Joint Broker)					T: [phone]
Rupert Dearden/ Freddy Crossley/ Emma Earl
FTI Consulting					T: [phone]
Simon Conway/ Ciara Martin

About Redx Pharma Plc

Redx Pharma (AIM: REDX) is a clinical-stage biotechnology company focused on the discovery and development of novel, small molecule, targeted therapeutics for the treatment of fibrotic disease, cancer and the emerging area of cancer-associated fibrosis. Redx aims to progress its programmes to clinical proof of concept before evaluating options for further development and potential value creation. The Company's lead fibrosis product candidate, the selective ROCK2 inhibitor, zelasudil (RXC007), is in development for interstitial lung disease and is undergoing a Phase 2a trial for idiopathic pulmonary fibrosis (IPF) with topline data expected in H1 2024. The Company's second fibrosis candidate, RXC008, a GI-targeted ROCK inhibitor for the treatment of fibrostenotic Crohn's disease, is in Phase 1 development with healthy volunteer data expected by the end of 2024. Redx's lead oncology product candidate, the Porcupine inhibitor zamaporvint (RXC004), being developed as a targeted treatment for Wnt-ligand dependent cancers, is expected to report anti-PD-1 combination Phase 2 data during the first half of 2024, following which Redx will seek a partner for ongoing development.

The Company has a strong track record of discovering new drug candidates through its core strengths in medicinal chemistry and translational science, enabling the Company to discover and develop differentiated therapeutics against biologically or clinically validated targets. The Company's accomplishments are evidenced not only by its wholly-owned clinical-stage product candidates and discovery pipeline, but also by its strategic transactions, which includes the sale of pirtobrutinib (RXC005, LOXO-305), the only non-covalent or reversible BTK inhibitor now approved by the US FDA, and transactions with both AstraZeneca and Jazz Pharmaceuticals.

To subscribe to Email Alerts from Redx, please visit: www.redxpharma.com/investor-centre/email-alerts/.   

 

END